[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335788-105":59,"doc-detail-335788-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","risk-of-autoimmunity-cancer-seeding-and-adverse-events-in-human-trials-of-whole-tissue-autologous-therapeutic-vaccines","Risk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines","","Whole-tissue autologous therapeutic vaccines (WATVs) use a patient’s own pathological tissue as cancer immunotherapy. Despite concerns that WATVs may trigger autoimmunity or enable cancer spread, their adverse events (AEs) have not been systematically characterized. This systematic review evaluates risks of autoimmunity and cancer seeding in human clinical trials and estimates AE incidence using CTCAE v5.0 grade 1–5. Results synthesize data from 55 sources covering 3,323 treated patients.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-of-autoimmunity-cancer-seeding-and-adverse-events-in-human-trials-of-whole-tissue-autologous-therapeutic-vaccines/335788/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-of-autoimmunity-cancer-seeding-and-adverse-events-in-human-trials-of-whole-tissue-autologous-therapeutic-vaccines/335788.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What are whole-tissue autologous therapeutic vaccines (WATVs)?","Question",{"text":112,"@type":113},"WATVs are personalized cancer immunotherapies that use a patient’s own tumor tissue to stimulate an immune response against disease. The approach is intended to preserve tumor-associated antigens present in the patient’s tissue.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the review assess risks of autoimmunity and cancer seeding?",{"text":117,"@type":113},"The review included human clinical trials in which the vaccine used the patient’s own tumor tissue. It searched published studies up to March 2024 and extracted evidence for autoimmunity, spreading/seeding of cancers, and other AEs.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the review find regarding autoimmunity and cancer seeding?",{"text":121,"@type":113},"The review reported no documented cases of WATV-induced autoimmunity and no documented cases of spreading/seeding of noninfectious cancers. For infectious cancers, the observed spreading/seeding risk was 0.24%, attributed to inadequate sterilization.",{"name":123,"@type":110,"acceptedAnswer":124},"What was the overall adverse event profile of WATVs?",{"text":125,"@type":113},"No deaths were attributed to WATV therapy. Grade 4 AEs occurred in 0.18% of patients, grade 3 AEs in 0.42%, and grades 1–2 in 52.21%. The combined risk of grade 3 and 4 AEs was 0.60%, with side effects comparable to routine vaccinations when properly sterilized.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335788,1790344033,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Cancer Pathogenesis and Therapy 3 (2025) 129–134  \nContents lists available at ScienceDirect  \nCancer Pathogenesis and Therapy  \njournal [homepage:](homepage: www.journals.elsevier.com/cancer-pathogenesis-and-therapy)[ www.journals.elsevier.com/cancer-pathogenesis-and-therapy](homepage: www.journals.elsevier.com/cancer-pathogenesis-and-therapy)  \nSystematic review  \nRisk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines  \nGarrett Gianneschi a, *, Anthony Scolpinob, James Oleskeb  \na Department of Neurology, Rutgers University-New Jersey Medical School, Newark, NJ 07103, USA  \nb Division of Immunology, Department of Pediatrics, Rutgers University-New Jersey Medical School, Newark, NJ 07103, USA  \nH I G H L I G H T S  \nA R T I C L E I N F O  \nManaging Editor: Peng Lyu  \nKeywords: Neoplasms Vaccination Autoimmunity Immunotherapy  \nDrug-related side effects and adverse reactions Systematic review  \nCancer vaccines  \nG R A P H I C A L A B S T R A C T  \n\n| |\n| --- |\n| A B S T R A C T |\n\nBackground: Whole-tissue autologous therapeutic vaccines (WATVs) are a form of cancer immunotherapy that use a patient's own pathological tissue. Concerns exist regarding the potential of WATVs to induce autoimmunity orthe spread of cancer; however, their adverse events (AEs) have not been adequately studied. This literature review primarily aimed to evaluate the risks of autoimmunity and cancer seeding associated with using WATVs in human clinical trials. Its secondary objectives included assessing the incidence of AEs graded 1–5 using the Common Terminology Criteria for Adverse Events v5.0.  \nMethods: The inclusion criteria were any clinical trial using human subjects in which at least part of the cancer vaccine was derived from the patient's own tumor tissue, which likely preserved the unique tumor-associated antigens (TAAs) present in the patient's tumor (i.e., whole-tissue). Tumor vaccine trials that used limited TAAs or highly processed tumor antigens were excluded. Published clinical trials were searched using Google Scholar until March 2024. The authors elaborated on the risk of bias in such cases, as indicated. All reviewed publications were searched for evidence of autoimmunity, cancer seeding, and other AEs. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement guided the review.  \nResults: Data from 55 human clinical trials, abstracts, case reports, and unpublished data were analyzed, including 3323 patients treated with WATVs for various cancers. The primary outcomes were: (1) no documented cases of WATV-induced autoimmunity,(2) no documented cases of WATV-induced spreading or seeding of noninfectious  \n* Corresponding author: Department of Neurology, Rutgers University - New Jersey Medical School, Newark, NJ 07103, USA.  \nE-mail address: [gbg30@rutgers.edu](gbg30@rutgers.edu) (G. Gianneschi).  \n[https://doi.org/10.1016/j.cpt.2024.05.003](https://doi.org/10.1016/j.cpt.2024.05.003)  \nReceived 24 February 2024; Received in revised form 20 May 2024; Accepted 26 May 2024  \n2949-7132/© 2024 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA). This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nG. Gianneschi et al. Cancer Pathogenesis and Therapy 3 (2025) 129–134  \ncancers, and (3) the observed 0.24%(2/838) risk of spreading or seeding infectious cancers was attributed to inadequate sterilization. The secondary outcomes were: (1) no deaths were attributed to WATV therapy, (2) 0.18%(6/3323) incidence of grade 4 AEs,(3) 0.42%(14/3323) incidence of grade 3 AEs,(4) the incidence of grades 1–2 AEs was 52.21%(478/916).  \nConclusions: WATVs carry no risk of inducing autoimmunity and essentially no risk of cancer seeding if properly sterilized. WATVs also exhibit a side effect proﬁle comparable to that of routine vaccinat","cbCaiqH43Xp08xBl","https://ap.wps.com/l/cbCaiqH43Xp08xBl","pdf",887458,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What are whole-tissue autologous therapeutic vaccines (WATVs)?\",\"answer\":\"WATVs are personalized cancer immunotherapies that use a patient’s own tumor tissue to stimulate an immune response against disease. The approach is intended to preserve tumor-associated antigens present in the patient’s tissue.\"},{\"question\":\"How did the review assess risks of autoimmunity and cancer seeding?\",\"answer\":\"The review included human clinical trials in which the vaccine used the patient’s own tumor tissue. It searched published studies up to March 2024 and extracted evidence for autoimmunity, spreading/seeding of cancers, and other AEs.\"},{\"question\":\"What did the review find regarding autoimmunity and cancer seeding?\",\"answer\":\"The review reported no documented cases of WATV-induced autoimmunity and no documented cases of spreading/seeding of noninfectious cancers. For infectious cancers, the observed spreading/seeding risk was 0.24%, attributed to inadequate sterilization.\"},{\"question\":\"What was the overall adverse event profile of WATVs?\",\"answer\":\"No deaths were attributed to WATV therapy. Grade 4 AEs occurred in 0.18% of patients, grade 3 AEs in 0.42%, and grades 1–2 in 52.21%. The combined risk of grade 3 and 4 AEs was 0.60%, with side effects comparable to routine vaccinations when properly sterilized.\"}]","Risk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines | PDF",1790012345,15]